


CLAIMS

1. A compound represented by Formula 1:

[Formula 1]



wherein R^1 to R^3 are each independently hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{1-10} alkoxy, substituted or unsubstituted C_{1-10} haloalkyl, substituted or unsubstituted C_{2-10} alkenyl, substituted or unsubstituted C_{2-10} alkynyl, substituted or unsubstituted C_{1-10} alkylene, substituted or unsubstituted C_{1-10} alkenylene, substituted or unsubstituted C_{1-10} alkynylene, substituted or unsubstituted C_{5-12} aryl, substituted or unsubstituted C_{7-12} arylalkyl, substituted or unsubstituted C_{5-14} arylalkynyl, substituted or unsubstituted C_{8-16} arylalkenyl, substituted or unsubstituted C_{3-10} heteroalkyl, substituted or unsubstituted C_{3-10} cycloalkyl, substituted or unsubstituted C_{3-10} heterocycloalkyl, or substituted or unsubstituted C_{5-12} heteroaryl, the heteroalkyl, heterocycloalkyl, or heteroaryl containing at least one of N, O, and S,

the substitution refers to a substitution with a non-hydrogen substituent, the non-hydrogen substituent may be at least one selected from the group consisting of $-X_1$, $-R_a$, $-O^-$, $=O$, $-OR_a$, $-SR_a$, $-S^-$, $-N(R_a)_2$, $-N^+(R_a)_3$, $=NR_a$, $-C(X_1)_3$, $-CN$, $-OCN$, $-SCN$, $-N=C=O$, $-NCS$, $-NO$, $-NO_2$, $=N-OH$, $=N_2$, $-N_3$, $-NHC(=O)R_a$, $-C(=O)R_a$, $-C(=O)NR_aR_a$, $-S(=O)_2O^-$, $-S(=O)_2OH$, $-S(=O)_2R_a$, $-OS(=O)_2OR_a$, $-S(=O)_2NR_a$, $-S(=O)R_a$, $-OP(=O)(OR_a)_2$, $-C(=O)R_a$, alkylene- $C(=O)R_a$, $-C(=S)R_a$, $-C(=O)OR_a$, alkylene- $C(=O)OR_a$, $-C(=O)O^-$, alkylene- $C(=O)O^-$, $-C(=S)OR_a$, $-C(=O)SR_a$, $-C(=S)SR_a$, $-C(=O)NR_aR_a$, alkylene- $C(=O)NR_aR_a$, $-C(=S)NR_aR_a$, and $-C(-NR_a)NR_aR_a$, X_1 is F, Cl, Br, or I, R_a is hydrogen, C_{1-6} alkyl, C_{5-12} aryl, C_{7-12} arylalkyl, or heterocycle,

R^4 and R^5 are each independently hydrogen, substituted or unsubstituted C_{1-6} alkyl, $-X_2$, $-R_b$, $-O^-$, $=O$, $-CH_2OR_b$, or $-OR_b$, X_2 is F, Cl, Br, or I, R_b is H,


substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₅₋₁₂ aryl, substituted or unsubstituted C₇₋₁₂ arylalkyl, or substituted or unsubstituted heterocycle,

R⁶ is hydrogen or substituted or unsubstituted C₁₋₆ alkyl, the substituent being -C(=O)NH₂,


R⁷ is hydrogen or C₁₋₆ alkyl, and

R⁸ and R⁹ are hydrogen or unsubstituted C₁₋₆ alkyl.

2. The compound of claim 1, wherein R¹ is selected from the group






3. The compound of claim 1, wherein R² is selected from the group



4. The compound of claim 1, wherein R³ is selected from the group

consisting of substituted or unsubstituted C₁₋₆ alkyl,








$\text{O}-\text{OR}_a$, and $\text{O}=\text{NHR}_a$, R_a is hydrogen or C_{1-6} alkyl, and n is an integer of 1 to 10.

5. The compound of claim 1, wherein R⁴ and R⁵ are each independently selected from the group consisting of substituted or unsubstituted C₁₋₆ alkyl, -OR_b, =O, -CH₂OR_b, and -X₂, and R_b is hydrogen or C₁₋₆ alkyl.











6. The compound of claim 5, wherein X₂ is F, Cl, Br, or I.

7. The compound of claim 1, wherein R⁶ to R⁹ are each independently hydrogen or substituted or unsubstituted C₁₋₆ alkyl, and the substituent is -C(=O)NH₂,


8. The compound of claim 2, wherein R¹ is selected from the group




consisting of




, and



9. The compound of claim 3, wherein R^2 is selected from the group



10. The compound of claim 4, wherein R^3 is one selected from the group



11. The compound of claim 6, wherein R^4 is selected from the group consisting of H, -OH, =O, and -CH₃.

12. The compound of claim 1, which is any one selected from the group consisting of HyP-Gly-Gln-Glu-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asn-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Gln-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-His-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Lys-Gly-Leu-Ala-Gly-

Pro-Lys, HyP-Gly-Gln-Ser-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Thr-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ala-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Val-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ile-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Phe-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Tyr-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Trp-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Ser(Homo)-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp(Me)-Gly-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asn(Me)-Gly-Leu-Ala-Gly-Pro-Lys, _D-Hyp(2R, 4S)-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, _D-Hyp(2R,4S)-Gly-_D-Gln-_D-Leu-Gly-_D-Leu-_D-Ala-Gly-_D-Pro-_D-Lys, _D-Hyp(2R, 4R)-Gly-_D-Gln-_D-Leu-Gly-_D-Leu-_D-Ala-Gly-_D-Pro-_D-Lys,

HyP-Gly-Gln-Asp-Val-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Ile-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Leu-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Ala-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Phe-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Tyr-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Trp-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-His-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Ser-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Asp-Thr-Leu-Ala-Gly-Pro-Lys, HyP-Gly-Gln-Leu-Ala-Leu-Ala-Gly-Pro-Lys,

HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Tyr, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Leu, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Glu, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Gln, HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Nle(6-OH), HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Ala, _D-Hyp(2R, 4S)-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Ala,

Hyp(2S, 4S)-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-oxo)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (5-oxo)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-hydroxyMe)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-Fluoro)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-Dimethyl)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (4-Me)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, (5-Me)Pro-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys,

Hyp-Gly-Ala-Leu-Gly-Leu-Ala-Gly-Pro-Lys, Hyp-Gly-Gln-Leu-Gly-Ala-Ala-Gly-Pro-Lys, Hyp-Gly-Gln-Leu-Gly-Leu-Ala-Ala-Pro-Lys, Hyp-Ala-Gln-


Leu-Gly-Leu-Ala-Gly-Pro-Lys, D -Hyp(2R, 4S)-Ala-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, and D -Hyp(2R, 4S)-Ala-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Ala.


13. A peptide having an amino acid sequence represented by HyP-Gly-Gln-Xaa-Gly-Leu-Ala-Gly-Pro-Lys, wherein Xaa is selected from the group consisting of Glu, Asn, Gln, His, Lys, Ser, Thr, Ala, Val, Ile, Leu, Phe, Tyr, Trp, homo-Ser, Asp(Me), and Asn(Me).

14. A peptide having an amino acid sequence represented by HyP-Gly-Gln-Asp-Xaa-Leu-Ala-Gly-Pro-Lys, wherein Xaa is selected from the group consisting of Val, Ile, Leu, Ala, Phe, Tyr, Trp, Ser, Thr, and (N-Me)Gly.

15. A peptide having an amino acid sequence represented by HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Xaa, wherein Xaa is selected from the group consisting of Tyr, Leu, Glu, Gln, Ala, and Nle(6-OH).

16. A peptide having an amino acid sequence represented by PD-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, wherein PD is any one selected from the group consisting of the following formulae:






17. A peptide having any one amino acid sequence selected from the group consisting of Ala-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys, Hyp-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Ala-Lys, HyP-Gly-Gln-Leu-Gly-Leu-Ala, HyP-Gly-Gln-Glu-Gly-Leu-Gly, HyP-Gly-Gln-Leu-Gly-Leu, D -HyP(2R, 4S)-Gly- D -Gln- D -Leu-Gly- D -Leu, HyP-Gly-Gln-Leu-Gly, HyP-Gly-Gln- D -Leu-Gly, and D -HyP(2R, 4S)-Gly-Gln-Leu-Gly.


18. A compound represented by Formula 8:

[Formula 8]



19. A compound represented by Formula 10:

[Formula 10]



20. A pharmaceutical composition for use in the treatment of an eye disease,

which comprises the compound according to any one of claims 1 to 12, 18, and 19, or the peptide according to any one of claims 13 to 17, as an active pharmaceutical ingredient.

21. The pharmaceutical composition of claim 20, wherein the eye disease is one selected from the group consisting of retinopathy, keratitis, dry-macular degeneration, wet-macular degeneration, dry eye syndrome, heratoconjunctivitis sicca and keratoconjunctival epithelium disorder.

22. Use of the compound according to any one of claims 1 to 12, 18, and 19, or the peptide according to any one of claims 13 to 17 in the manufacture of a pharmaceutical composition for treating an eye disease.